BIOMAT Database Logo BIOMAT Database Logo

Phase II study of a 21-day continuous infusion schedule with epirubicin in metastatic colorectal cancer. 1988

J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
Department of Internal Medicine, University Hospital, Groningen, The Netherlands.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
September 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
January 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients.
January 2005, Anticancer research,
J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.
January 1993, European journal of cancer (Oxford, England : 1990),
J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer.
November 1993, Cancer,
J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
May 1996, British journal of cancer,
J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.
August 1998, European journal of cancer (Oxford, England : 1990),
J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
Phase II study of five-day continuous infusion of vinblastine in patients with metastatic renal-cell carcinoma.
June 1987, American journal of clinical oncology,
J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule.
August 1984, Cancer research,
J Greidanus, and P H Willemse, and D T Sleijfer, and N H Mulder, and R C Verschueren, and R Nieweg, and E G de Vries
A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
February 2016, BMC cancer,
Copied contents to your clipboard!